Blockchain Registration Transaction Record

VolitionRx Partners with Hologic to Expand Nu.Q® Discover Service Access

VolitionRx partners with Hologic to co-market Nu.Q® Discover epigenetic assays, expanding access to $200M market for drug developers and scientists in oncology and disease research.

This partnership between VolitionRx and Hologic represents a significant advancement in pharmaco-epigenetics that could accelerate drug development across multiple disease areas. For patients, this collaboration means potentially faster development of new treatments and improved diagnostic tools for conditions ranging from cancer to cardiovascular and neurodegenerative diseases. The expanded access to Nu.Q® Discover assays through Hologic's established network could lead to more efficient clinical trials and better understanding of disease mechanisms, ultimately resulting in earlier detection and more personalized treatment approaches. In the broader healthcare landscape, this agreement demonstrates the growing importance of epigenetic profiling in modern medicine and could set new standards for how pharmaceutical companies approach drug development and disease monitoring.